Roche Holding AG

DelveInsight's 2025 pipeline report reveals over 20 companies actively developing more than 20 innovative therapies for HER2-positive gastric cancer treatment.

A comprehensive analysis of the global Graft Versus Host Disease clinical trial landscape shows significant activity across G7 and E7 countries, offering strategic insights for pharmaceutical companies.

DelveInsight's 2025 pipeline report reveals more than 200 companies developing 220+ therapies for Non-Hodgkin's Lymphoma, demonstrating robust research activity in this therapeutic area.

DelveInsight's latest report reveals a robust B-cell lymphoma pipeline with over 295 companies developing 300+ therapies, highlighting significant industry investment in this area.

Biosimilars must demonstrate close similarity to reference products in quality, non-clinical, and clinical data, while biobetters are purposely differentiated to deliver improvements over originators.

Roche Holding AG announces plans to introduce innovative sequencing by expansion technology in 2024, potentially disrupting Illumina's long-standing market leadership in next-generation sequencing.

• The global market for breakthrough therapies is projected to grow from $150.6 billion in 2024 to $287.5 billion by 2029, representing a compound annual growth rate of 13.8%. • Expedited regulatory pathways, including the FDA's Breakthrough Therapy Designation and EMA's PRIME scheme, are accelerating development of innovative treatments for serious conditions like cancer and cardiovascular disease. • Recent success stories include AbbVie's epcoritamab for follicular lymphoma and Merck's sotatercept-csrk (WINREVAIR) for pulmonary arterial hypertension, both receiving breakthrough designations.

• The lupus nephritis clinical trial pipeline is robust, featuring over 30 companies developing more than 35 therapies. • Key players like AstraZeneca, Roche, and Novartis are advancing drugs such as Anifrolumab and Ianalumab through clinical trials. • Recent trial activities include Adicet Bio dosing the first patient in a Phase I trial of ADI-001 and Kyverna presenting updated clinical data on KYV-101. • Various therapeutic modalities, including monoclonal antibodies and cell therapies, are being explored across different clinical stages.

The global biotechnology market is expected to grow from USD 1.68 trillion in 2024 to USD 3.54 trillion by 2033, representing a CAGR of 9.18%, according to Cervicorn Consulting.

The weight loss drugs market is projected to grow at an annual rate of 43.73% through 2032, driven by rising obesity rates and increased employer coverage.